BridgeBio Pharma, Inc. · NASDAQ:BBIO
BridgeBio Pharma — Technical Presentation (June 2022)
12 slides from BridgeBio Pharma's technical presentation, Jun 9, 2022
Slide 1: Preliminary results from open-label escalating-dose cohort study of VT30 (Study VT30-101)
Preliminary results from an open-label escalating-dose cohort study of VT30, a topically formulated phosphatidylinositol 3- kinase inhibitor (PI3K), intended as a treatment for patients with cutaneous vascular malformations associated with underlying PIK3CA or TEK mutations (Study VT30-101) Clinical
Slide 2: Disclosures
Disclosures • Founder: Venthera • Speaker: Novartis; Sanofi; Pfizer; Leo; Pierre Fabre Dermatologie • PI: Novartis; Sanofi; Pierre Fabre Dermatologie; Leo; Eli Lilly; Pfizer 2
Slide 3: VT30-101 First-in-Human Study Objectives
VT30-101 First-in-Human Study Objectives • Characterize the safety & tolerability of VT30 Topical Gel ⎼Define maximum tolerated dose (MTD) or maximum feasible dose (MFD) • Assess plasma drug levels • Exploratory ⎼Tissue drug levels ⎼Tissue pharmacodynamics ⎼Imaging ⎼Efficacy – patient and investigat
Slide 4: VT30-101 Study Design
VT30-101 Study Design Key Inclusion Criteria • 18 to 60 years of age • Informed consent • Have a clinically or phenotypically defined VM, LM, or mixed VLM affecting the skin (may also have capillary involvement and/or extend to affect subcutaneous tissue) • Lesion amenable to defining a contiguous s
Slide 5: VT30-101: Subject Disposition & Characteristics
VT30-101: Subject Disposition & Characteristics ⎼ 29 potential subjects formally screened Cohort Subject Se Age Treatment Genotype Lesion Location Number x (yrs) Type ⎼ 15 were allocated to treatment 112-001 M 30 0.12 -->0.6% TEK VM abdomen • Most common reasons for screen failure 1 112-003 F 47 0.1
Slide 6: VT30 Safety & Tolerability: Rash – only finding of note
VT30 Safety & Tolerability: Rash – only finding of note Apparent dose or exposure relationship with observed incidence Cohort Subject Sex Age (yrs) Treatment Genotype Lesion Location • 4 patients developed a local dermatitis/rash Number Type on gel strengths of 1.2% or higher ( 2 missed 112-001 M 30
Slide 7: Tissue-Drug Levels in Multiple-fold Excess of IC50 for PI3Kα Inhibition
Tissue-Drug Levels in Multiple-fold Excess of IC50 for PI3Kα Inhibition • VT30 is efficiently converted to VT10 after permeation of the epidermal stratum corneum • VT10 is the active drug form in and in proximity to the dermis • VT10 IC50 for pS6rp in cell-based assays = 200 – 400 nM; IC50 for PI3Ka
Slide 8: Tissue Pharmacodynamics: suppression of dermal pS6rp levels
Tissue Pharmacodynamics: suppression of dermal pS6rp levels on immunofluorescent staining Preliminary Data – Patients with biopsies unconfounded by skin rash • Consistent with high drug levels Median pS6rp area, assessed by immunofluorescence, normalized to documented in tissue evaluable dermis – pr
Slide 9: Standardized Imaging of Treatment Area Conducted as an Exploratory Methodology
Standardized Imaging of Treatment Area Conducted as an Exploratory Methodology • Feasibility and utility confirmed • Investigators sized treatment areas, per protocol, via digital tracing • Successful documentation of biopsy sites and of lesion space within the treatment area • High resolution 3D re
Slide 10: Patient 113-004: 0.6% x 4 wks
Patient 113-004: 0.6% x 4 wks Visit 2, pre-treatment Visit 4, day 28 of treatment Visit 5, post-treatment follow up Genotype: PIK3CA mutation E453_L455 del 10
Slide 11: Exploratory Efficacy: Baseline Mean and Mean Change after 4 Weeks
Exploratory Efficacy: Baseline Mean and Mean Change after 4 Weeks of Topical Study Treatment • Preliminary Results: Pending Completion of Database • We measured Investigator Global, Pain, Bleeding and oozing, and Patient Global assessment • Observed a slight improvement in Bleeding and Oozing and In
Slide 12: VT30-101: Summary and Conclusions
VT30-101: Summary and Conclusions • 0.6% VT30 Topical Gel (once daily) is appropriate as a dose-strength for longer term study ⎼ Acceptable tolerability out to 4 weeks • Potential for contact dermatitis requires further clarification ⎼ Generates drug levels in the skin well in excess of concentratio
BridgeBio Pharma — Technical Presentation (June 2022) on 6ix